SEC Comment Letter 0000000000-24-008186 to Climb Bio, Inc. (CLYM) (CIK 0001768446) (CLYM)
Climb Bio, Inc. (CLYM) (CIK 0001768446)
Date: July 18, 2024 · CIK: 0001768446 · Accession: 0000000000-24-008186
AI Filing Summary & Sentiment
File numbers found in text: 333-280784
Letter
July 18, 2024 Aoife Brennan President and Chief Executive Officer Eliem Therapeutics, Inc. PMB #117 2801 Centerville Road 1st Floor Wilmington, DE 19808-1609 Re:Eliem Therapeutics, Inc. Registration Statement on Form S-3 Filed July 12, 2024 File No. 333-280784 Dear Aoife Brennan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Laura Crotty at 202-551-7614 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Chris Barnstable-Brown
Show Raw Text
July 18, 2024
Aoife Brennan
President and Chief Executive Officer
Eliem Therapeutics, Inc.
PMB #117
2801 Centerville Road 1st Floor
Wilmington, DE 19808-1609
Re:Eliem Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 12, 2024
File No. 333-280784
Dear Aoife Brennan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Laura Crotty at 202-551-7614 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Chris Barnstable-Brown